drugset / Trial / NCT00619866

An Efficacy and Safety Study of Elagolix (NBI-56418) in Women With Endometriosis

NCT00619866

Phase 2 Completed 155 enrolled AbbVie
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study is designed to see how elagolix works compared to placebo in women with endometriosis and to see the effect, if any, on bone mineral density.

Timeline

Start
2008-02-19
Primary completion
2009-04-20
Completion
2009-08-28

Drugs

EvaluationDrugModalityDoseRoute
Subject Elagolix Small molecule 150 mg Oral
Subject Elagolix Small molecule 250 mg Oral

Indications